KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Quest Diagnostics (DGX) EBIT (2016 - 2026)

Quest Diagnostics' EBIT history spans 18 years, with the latest figure at $399.0 million for Q1 2026.

  • On a quarterly basis, EBIT rose 15.32% to $399.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $1.6 billion, a 15.59% increase, with the full-year FY2025 number at $1.6 billion, up 15.6% from a year prior.
  • EBIT hit $399.0 million in Q1 2026 for Quest Diagnostics, up from $386.0 million in the prior quarter.
  • Over the last five years, EBIT for DGX hit a ceiling of $513.0 million in Q1 2022 and a floor of $135.0 million in Q4 2022.
  • Historically, EBIT has averaged $352.4 million across 5 years, with a median of $355.0 million in 2024.
  • Biggest five-year swings in EBIT: crashed 74.81% in 2022 and later soared 97.78% in 2023.
  • Tracing DGX's EBIT over 5 years: stood at $135.0 million in 2022, then surged by 97.78% to $267.0 million in 2023, then skyrocketed by 35.21% to $361.0 million in 2024, then rose by 6.93% to $386.0 million in 2025, then grew by 3.37% to $399.0 million in 2026.
  • Business Quant data shows EBIT for DGX at $399.0 million in Q1 2026, $386.0 million in Q4 2025, and $386.0 million in Q3 2025.